Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
NCT07106879
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cardiovascular Diseases
- Metabolic Syndrome
- Obesity
- Prediabetes
- Mental Health Disorders
- Endocrine Dysfunction
- Type 2 Diabetes Mellitus (T2DM)
- Chronic Kidney Disease (CKD)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Clindove Research LLC
- Last updated on ClinicalTrials.gov
- August 12, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Clindove Research LLC · Brooklyn, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.